UPMC
LIFE CHANGING MEDICINE

Don’t Wait for the Weight: Proactive Management of SGA-Associated Metabolic Effect

Jaxon Carter, PharmD
PGY1 Pharmacy Resident
UPMC Western Psychiatric Hospital

Continuing Education Information

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (CPE)

This knowledge-based activity provides **1.0 contact hours** of continuing pharmacy education credit

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Disclosures

Dr. Carter and other members of the planning committee have relevant financial relationships with any entity of producing, marketing, re-selling, or distributing health goods or services, used on, or consumed by patients to disclose.

Disclaimer

The information presented at this Center for Continuing Education in Health Sciences program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Learning Objectives

1. Describe the metabolic risks associated with second-generation antipsychotic therapy and the rationale for early preventive intervention.
2. Compare the efficacy, safety, and clinical evidence for metformin and GLP-1 receptor agonists in preventing or managing SGA-associated metabolic effects.
3. Identify factors that inform when preventive pharmacotherapy should be initiated in patients starting an SGA.